A review of cancer immunotherapy: from the past, to the present, to the future von Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S., Papneja, N., Miller, W. H.

Volltext

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study von Maio, M., Ascierto, P.A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus Acosta, A., Doi, T., Longo, F., Miller, W.H., Oh, D.-Y., Gottfried, M., Xu, L., Jin, F., Norwood, K., Marabelle, A.

Volltext

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy von Hoffer, L.J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S.J., Rosadiuk, K., Rousseau, C., Robitaille, L., Miller, W.H.

Volltext

Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial von Rodon, J., Soria, J.C., Berger, R., Batist, G., Tsimberidou, A., Bresson, C., Lee, J.J., Rubin, E., Onn, A., Schilsky, R.L., Miller, W.H., Eggermont, A.M., Mendelsohn, J., Lazar, V., Kurzrock, R.

Volltext

A phase I study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, for intravenous (IV) administration in patients with advanced solid tumors von Razak, A, Gore, L, Britten, C.D, Miller, W.H, Uy, G.L, Nichols, G, Middleton, S, Blotner, S, Zhi, J, Jukofsky, L, Pierceall, W, Higgins, B, Chen, L.C

Volltext

The atmospheric neutrino flavor ratio from a 3.9 fiducial kiloton-year exposure of Soudan 2 von Allison, W.W.M., Alner, G.J., Ayres, D.S., Barr, G., Barrett, W.L., Bode, C., Border, P.M., Brooks, C.B., Cobb, J.H., Cotton, R.J., Courant, H., Demuth, D.M., Fields, T.H., Gallagher, H.R., Garcia-Garcia, C., Goodman, M.C., Gran, R., Joffe–Minor, T., Kafka, T., Kasahara, S.M.S., Leeson, W., Litchfield, P.J., Longley, N.P., Mann, W.A., Marshak, M.L., Milburn, R.H., Miller, W.H., Mualem, L., Napier, A., Oliver, W.P., Pearce, G.F., Peterson, E.A., Petyt, D.A., Price, L.E., Ruddick, K., Sanchez, M., Schneps, J., Schub, M.H., Seidlein, R., Stassinakis, A., Thron, J.L., Vassiliev, V., Villaume, G., Wakely, S., Wall, D., West, N., Wielgosz, U.M.

Volltext

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors von Hellmann, M.D., Kim, T.-W., Lee, C.B., Goh, B.-C., Miller, W.H., Oh, D.-Y., Jamal, R., Chee, C.-E., Chow, L.Q.M., Gainor, J.F., Desai, J., Solomon, B.J., Das Thakur, M., Pitcher, B., Foster, P., Hernandez, G., Wongchenko, M.J., Cha, E., Bang, Y.-J., Siu, L.L., Bendell, J.

Volltext

Theories of intramolecular vibrational energy transfer von Uzer, T., Miller, W.H.

Volltext

Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3 von Robichaud, N, del Rincon, S V, Huor, B, Alain, T, Petruccelli, L A, Hearnden, J, Goncalves, C, Grotegut, S, Spruck, C H, Furic, L, Larsson, O, Muller, W J, Miller, W H, Sonenberg, N

Volltext

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer von Aglietta, M., Barone, C., Sawyer, M.B., Moore, M.J., Miller, W.H., Bagalà, C., Colombi, F., Cagnazzo, C., Gioeni, L., Wang, E., Huang, B., Fly, K.D., Leone, F.

Volltext

1071TiP Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors von Dummer, R., Daud, A., Eigentler, T.K., Evans, T.R.J., Henry, J., Hodi, F.S., Miller, W.H., Robert, C., Saibil, S., Tachiki, L., Nayeri, M., Xing, B., Mehnert, J.M.

Volltext

616MO Long-term follow-up of single-agent divarasib in patients with KRAS G12C-positive solid tumors von Garralda, E., Patel, M.R., Kim, T.W., Sacher, A.G., Forster, M.D., Santoro, A., Desai, J., Paz-Ares, L.G., Falcon Gonzalez, A., De Miguel, M., Bowyer, S.E., Dziadziuszko, R., Kim, S.H., Han, S-W., Krebs, M.G., Lorusso, P., Cosman, R., Chang, J., Jun, T., Miller, W.H.

Volltext

537P A phase I/II study of oral chk1 inhibitor LY2880070 in combination with low-dose gemcitabine in patients with advanced or metastatic ovarian cancer von Miller, W.H., Shields, A.F., Provencher, D., Gilbert, L., Shapiro, G., Oza, A.M., Spratlin, J., Lheureux, S., Bhat, G., Salvador, S., Nunes, P., Lau, S., Weiner, I., Keene, J., Zaknoen, S., Smith, P., Stille, J., Vincett, D., Chu, Q.S-C.

Volltext

113P Pembrolizumab in microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) advanced solid tumors: An update of the phase II KEYNOTE-158 trial von Maio, M., Ascierto, P.A., Motola Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus-Acosta, A., Doi, T., Longo Muñoz, F., Miller, W.H., Oh, D-Y., Gottfried, M., Yao, L., Jin, F.J., Gozman, A., Marabelle, A.

Volltext

546P Pembrolizumab for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial cancer: Long-term follow-up results from KEYNOTE-158 von O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus-Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Yao, L., Gozman, A., Jin, F.J., Maio, M.

Volltext

743P A phase Ib dose escalation study of CD137 mAb agonist OC-001 as monotherapy in patients with advanced or metastatic cancer von Miller, W.H., Provencher, D., Chu, Q.S-C., Jonker, D., Oza, A.M., Batist, G., Jamal, R., Goel, R., Hilton, J.F., Spratlin, J., Smith, P., Darling, I., Stille, J., Fortier, C., Mangat, R., Polzer, J.

Volltext

3310 LOGIC2: Phase 2, multi-center, open-label study of sequential encorafenib/binimetinib combination followed by a rational combination with targeted agents after progression, to... von Dummer, R, Sandhu, S, Hassel, J.C, Muñoz, E, Berking, C, Gesierich, A, Ascierto, P.A, Esposito, O, Carter, K, Antona, V, Radhakrishnan, R, Cui, X, Caponigro, G, Jaeger, S, Demuth, T, Miller Jr, W.H

Volltext

Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial can... von O'Malley, D.M., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Amonkar, M., Yao, L., Jin, F., Norwood, K., Maio, M.

Volltext

797P Health-related quality of life (HRQoL) with pembrolizumab (pembro) monotherapy in patients (pts) with previously treated advanced microsatellite instability high (MSI-H) endom... von O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Amonkar, M., Xu, L., Jin, F., Norwood, K., Maio, M.

Volltext

795MO Pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): Updated results from KEYNOTE-158 von O'Malley, D., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Xu, L., Jin, F., Norwood, K., Maio, M.

Volltext